SERD Therapeutics Market Report Latest Trends and Future Opportunities Analysis

InsightAce Analytic Pvt. Ltd. announces the release of market assessment report on "Global SERD Therapeutics Market by Products (Faslodex, Elacestrant, Camizestrant (AZD9833), Giredestrant (GDC-9545), Imlunestrant (LY3484356), Other Pipeline Products), By Indication (ER-positive, HER2-negative, ESR1-mutated advanced or Metastatic Breast Cancer) - Industry Analysis, Competitive Landscape, Revenue Forecast 2024-2031".

The SERD Therapeutics Market Size is valued at 1508.0 Million in 2022 and is predicted to reach 6382.2 Million by the year 2031 at a 17.5 % CAGR during the forecast period for 2024-2031.

Get A Free Report Brochure: https://www.insightaceanalytic.com/request-sample/1246

Major driving factors in the SERD therapeutics market are the increasing need for SERD therapies, the high prevalence of breast cancer, rising number of clinical trials. Furthermore, the fast adoption of advanced medical technologies, population growth, and a growing number of health-conscious people will enhance the growth of the SERD therapeutics market.

However, the high price of devices, complex procedures, and resistance to endocrine therapy is restraining the development of this market. Moreover, the COVID-19 pandemic has both positively and negatively impacted the SERD therapeutics market due to the lockdown situations.

Major key Players in the SERD therapeutics market are
• Amneal Pharmaceuticals Inc
• AstraZeneca, Plc.
• Reddy's Laboratories
• Eli Lilly and Company
• G1 Therapeutics, Inc.
• Glenmark Pharmaceuticals
• HBT Labs, Inc
• Hoffmann-La Roche AG
• InventisBio
• Novartis AG
• Radius Health
• Sanofi S.A.
• Teva Pharmaceutical Industries Ltd.
• Zenopharm LLC.
• Zentalis Pharmaceuticals
• Genentech
• Olema Pharmaceuticals
• Aragon Pharmaceuticals
• Sun Pharma Advanced Research Company
• Shandong Luoxin Pharmaceutical
• Zeno Alpha
• Atossa Therapeutics
• Evestra

Recent Key Developments:
• In June 2021, Eli Lilly and Company presented new results for the exploratory use of Verzenio® (abemaciclib) in high-risk early breast cancer, as well as for its oral selective oestrogen receptor degrader (SERD) LY3484356 (ASCO). Lilly is releasing an exploratory analysis from the positive Phase 3 monarch study testing Verzenio, a CDK4/6 inhibitor, in a subset of patients with HR+, HER2-, high-risk early breast cancer (EBC) who had had neoadjuvant chemotherapy.
• In Sept 2020, InventisBio recently announced the conclusion of a $147 million series D fundraising, which included several of the world's leading biopharmaceutical and healthcare venture capital firms. InventisBio currently has three medicinal compounds in various stages of clinical development, and one new product has recently begun a worldwide phase I clinical trial. D-0502 showed remarkable anti-tumour effectiveness in phase 1 research, with superior absorption and an acceptable safety profile when compared to other oral SERDs in clinical development throughout the world.
• In Sept 2019, Preliminary data from a Phase 1/2a dose-escalation trial of G1T48, an oral selective oestrogen receptor degrader (SERD), in patients with oestrogen receptor-positive, HER2-negative (ER+, HER2-) breast cancer were released by G1 Therapeutics, Inc. G1T48 was well tolerated in the study and showed anti-tumour effectiveness in patients who had been substantially pre-treated. The results of this trial support the future development of G1T48 in both first line and adjuvant settings, and a first-line Phase 3 pivotal trial is expected to begin in 2020.

Enquiry Before Buying: https://www.insightaceanalytic.com/enquiry-before-buying/1246

Selective estrogen receptor degrader (SERD) is a type of drug which downregulates the estrogen receptor. SERD and full receptor antagonist are essential treatment options for HR-positive breast cancer. Tamoxifen, a particular estrogen receptor modulator (SERM) with receptor agonist and antagonist action, and aromatase inhibitors, which prevent estrogen production, but cause acquired resistance, are examples of endocrine medicines. Fulvestrant, the only SERD currently licensed, has weak drug-like characteristics.

The development of oral SERDs with optimal target occupancy and potency and enhanced clinical performance has been a primary emphasis for improving disease management. The increasing investments by key players in the development of promising breast cancer therapies are anticipated to fuel the SERD therapeutics market growth over the forecast period.

At the regional level, the North American region is the major revenue holder of this market due to rising awareness about SERD therapies, increasing government investments in the research and development of therapies for the treatment of various cancer diseases, and the rising prevalence of breast cancer. On the other hand, the Europe region will also dominate the market during the forecast period due to the advancements in the biopharmaceutical field, stringent regulations, and the increasing prevalence of chronic diseases. The Asia-Pacific market is projected to show significant growth in the future due to the growing SERD therapeutic industries and fast adaption of new technologies.

Leading manufacturers in this field are focusing on novel SERD therapy innovations, making new partnerships, collaborations and agreements, growing awareness about SERD therapies, and increasing research investments for developing advanced technologies. These strategies will propel their growth opportunities in the market. In 2020, QLHC announced an evaluation of Sanofi's SAR439859, an oral estrogen receptor degrader (SERD), in a new I-SPY 2 study arm targeting patients with newly diagnosed hormone receptor-positive (HR+) clinical stage 2/3 invasive breast cancer. AstraZeneca moved its next-generation oral SERD AZD9833 into phase 1 in 2018. While work on AZD9496 stalled after a few early clinical trials, AstraZeneca has quickly expanded and advanced the development of AZD9833. Late last month, AstraZeneca began enrolling patients in the phase 3 clinical trial of AZD9833.

Get Specific Chapter/Information From The Report: https://www.insightaceanalytic.com/customisation/1246

Market Segments
Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2023 to 2031 based on Products
• Faslodex
• Elacestrant
• Camizestrant (AZD9833)
• Giredestrant (GDC-9545)
• Imlunestrant (LY3484356)
• Other Pipeline Products
Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2023 to 2031 based on Route Of Administration
• Intramuscular
• Oral
• Infusion
• Subcutaneous
• Parenteral
• Other
Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2023 to 2031 based on Indication
• ER-positive
• HER2-negative
• ESR1-mutated advanced or metastatic breast cancer
• Other

Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2023 to 2031 based on Region
• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa
North America SERD therapeutics market revenue (US$ Million) by Country, 2023 to 2031
• U.S.
• Canada
Europe SERD therapeutics market revenue (US$ Million) by Country, 2023 to 2031
• Germany
• France
• Italy
• Spain
• Russia
• Rest of Europe
Asia Pacific SERD therapeutics market revenue (US$ Million) by Country, 2023 to 2031
• India
• China
• Japan
• South Korea
• Australia & New Zealand
Latin America SERD therapeutics market revenue (US$ Million) by Country, 2023 to 2031
• Brazil
• Mexico
• Rest of Latin America

Middle East & Africa SERD therapeutics market revenue (US$ Million) by Country, 2023 to 2031
• GCC Countries
• South Africa
• Rest of Middle East & Africa

Why should buy this report:
> To receive a comprehensive analysis of the prospects for global SERD therapeutics market
> To receive industry overview and future trends of global SERD therapeutics market
> To analyse the SERD therapeutics market drivers and challenges
> To get information on SERD therapeutics market size value (US$ Mn) forecast till 2030
> Major Investments, Mergers & Acquisition in global SERD therapeutics market industry

For More Information: https://www.insightaceanalytic.com/report/global-serd-therapeutics-market/1246

Other Related Reports Published by InsightAce Analytic:
Global RNA-based Therapeutics Market
Global Stem Cell Exosome Therapeutic Market
Global Antisense Oligonucleotide Therapeutics Market
Global Oncolytic Virus Therapy Market
Global Immuno-Oncology Cell Therapy Market

Sales Office (U.S.) :
344 Grove St Unit #967 Jersey City, NJ 07302
info@insightaceanalytic.com
North America:
+1 551 226 6109
Asia:
+91 79 72967118

About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

Contact US:
InsightAce Analytic Pvt. Ltd.
Tel.: +1 718 593 4405
Email: info@insightaceanalytic.com
Site Visit: www.insightaceanalytic.com
Follow Us on LinkedIn @ bit.ly/2tBXsgS
Follow Us On Facebook @ bit.ly/2H9jnDZ

This release was published on openPR.